Researchers engineered an iRGD-PLGA nanocomplex designed to target colon cancer drug resistance. The platform combines iRGD tumor-targeting behavior with PLGA delivery chemistry and is positioned to address resistance and metastatic spread, which remain major constraints for effective treatment. The disclosure frames the strategy as a targeted nanomedicine approach intended to improve delivery to resistant tumor populations and enhance therapeutic effect when conventional regimens fail. The report adds to the growing set of nanoparticle-and-ligand designs aimed at directing payloads to difficult-to-treat tumor microenvironments.